edoxaban
daiichi sankyo
['edoxaban']
6564 giovanardi: pros with edoxaban in cancer pts. qol and satisfaction with doac therapy was preserved for 6 months during concurrent cancer tx. wonderful to see pros in the classical heme space. #asco23 #hemetwitter 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈